Pathological and clinical characteristics of DLBCL patients
| Pathological feature | DLBCL HCV+ | DLBCL HCV− |
|---|---|---|
| Total | 19 | 18 |
| Mean age in year, value (range) | 67 (41–83) | 70 (32–91) |
| Male sex, number of cases (%) | 12 (63) | 11 (61) |
| HCV-RNA virus, number of cases (%) | 19 (100) | NA |
| HCV-Ab positive*, number of cases (%) | 19 (100) | NA |
| HCV- genotype 1, number of cases (%) | 5 (26) | NA |
| HCV- genotype 2, number of cases (%) | 14 (74) | NA |
| Bone marrow infiltration, number of cases (%) | 6 (31) | 4 (22) |
| Liver involvement number of cases (%) | 4 (21) | 1 (5) |
| Splenomegaly, number of cases (%) | 5 (26) | 2 (11) |
| Germinal centre subtype number of cases (%) | GCB: 5 (26) | GCB: 5 (28) |
| No-GCB: 14 (74) | No-GCB: 13 (72) | |
| Stage, number of cases (%) | I-II: 10 (52) | I-II: 11 (61) |
| III-IV: 9 (48) | III-IV: 7 (39) | |
| International Prognostic Index, number of cases (%) | 1–2: 11(58) | 1–2: 11 (61) |
| 3–4: 8 (42) | 3–4: 7 (39) | |
| Follow up period: mean (range) | 28 (3–90) | 23 (3–70) |
| Death, number of cases (%) | 11 (61) | 9 (50) |
*HCV-antibodies were evaluated by second-generation ELISA.
DLBCL, diffuse large B-cell lymphoma; HCV, hepatitis C virus.
Ab, antibody; NA, not applicable.